Notwithstanding the significant decline in healthtech valuations in India over recent years, the market has now stabilized with surviving companies being fairly valued, according to Biju Mohandas, Partner and Global Head of Healthcare Investments at LeapFrog Investments, a global impact fund backed by Singapore’s Temasek.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
